SAN DIEGO, CA--(Marketwired - Mar 3, 2016) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) (OTCQB: INNV) a company focusing on the commercialization of over-the-counter ("OTC") and consumer products for men's and women's health, vitality and respiratory diseases, announced today that it has received the 2016 coveted Five Star Spectrum Award for Customer Service Excellence.

CityBeat News ("CBN") is one of the most respected research and publishing companies in the United States. Their primary focus is identifying outstanding small to mid-size companies across the country, using a variety of sources, rankings, and assessments. CBN is not a customer review site, and they are known for only nominating those businesses with the top ratings in their specialized fields of service.

The Spectrum Award for Excellence is unique in that it reflects overall customer satisfaction, without bias. The information presented by CBN is then available as a tool to assist potential clients in choosing a trusted business in the future. Additionally, the Spectrum Award tells employees that they are doing a good job, and empowers them to continue the hard work.

"It is most affirming to know that an important industry monitor confirms our mission to provide elite customer service," stated Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. "We ask our team to provide a standard of excellence that mirrors the premium quality of our product line and this award tells me we're doing it."

For more information on the City Beat News' Spectrum Award for Excellence, go to

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products Zestra® for female arousal and EjectDelay® for premature ejaculation and has a total of five marketed products in this space, including Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), Zestra Glide®, Vesele® for promoting sexual and cognitive health, Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

For more information, go to,;;;; and

Innovus Pharma's Forward-Looking Safe Harbor: Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to receive approval or meet the requirements of any relevant regulatory authority, to successfully commercialize such products (Zestra®, Zestra Glide®, EjectDelay®, Sensum and Vesele®) and to achieve its other development, commercialization and financial goals, whether the new distributors will continue to successfully market and sell our products and close the acquisition of the Beyond Human assets. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contact Information:

Innovus Pharma Contact:
Reuven Rubinson
Vice President of Finance
T: 858-964-5123